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Abstract
AIM: To examine the frequency of regular comple-
mentary and alternative therapy (CAM) use in three 
Australian cohorts of contrasting care setting and 
geography, and identify independent attitudinal and 
psychological predictors of CAM use across all cohorts. 
METHODS: A cross sectional questionnaire was 
administered to inflammatory bowel disease (IBD) 
patients in 3 separate cohorts which differed by 
geographical region and care setting. Demographics 
and frequency of regular CAM use were assessed, 
along with attitudes towards IBD medication and 
psychological parameters such as anxiety, depression, 
personality traits and quality of life (QOL), and 
compared across cohorts. Independent attitudinal and 
psychological predictors of CAM use were determined 
using binary logistic regression analysis. 
RESULTS: In 473 respondents (mean age 50.3 years, 
60.2% female) regular CAM use was reported by 
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45.4%, and did not vary between cohorts. Only 54.1% 
of users disclosed CAM use to their doctor. Independent 
predictors of CAM use which confirm those reported 
previously were: covert conventional medication 
dose reduction (P  < 0.001), seeking psychological 
treatment (P  < 0.001), adverse effects of conventional 
medication (P  = 0.043), and higher QOL (P  < 0.001). 
Newly identified predictors were CAM use by family or 
friends (P  < 0.001), dissatisfaction with patient-doctor 
communication (P  < 0.001), and lower depression 
scores (P  < 0.001). 
CONCLUSION: In addition to previously identified 
predictors of CAM use, these data show that physician 
attention to communication and the patient-doctor 
relationship is important as these factors influence CAM 
use. Patient reluctance to discuss CAM with physicians 
may promote greater reliance on social contacts to 
influence CAM decisions.  
Key words: Complementary medicine; Alternative 
therapy; Therapy; Inflammatory bowel disease; Patient-
Doctor Communication; Medication adherence
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Complementary medicine use is widespread in 
inflammatory bowel disease, and potentially deleterious 
to treatment outcomes. Whilst demographic and clinical 
predictors of complementary and alternative therapy 
(CAM) are well established, attitudinal influences are 
under explored. This study demonstrates that the 
specific aspect of patient doctor relationship most 
influencing CAM use is quality of doctor communication. 
The other newly identified predictor of CAM use is its 
use by family and friends. This finding enables valuable 
insight suggesting that in the absence of good doctor 
communication, inflammatory bowel disease patients 
seek advice from unqualified sources such as family 
and friends.
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complementary medicine use in inflammatory bowel disease. 
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INTRODUCTION
The use of complementary and alternative medicine 
(CAM) is widespread in inflammatory bowel disease 
(IBD), rates ranging from 31% to 74% in studies 
across Europe[1-3], Australasia[4,5], and North America[6]. 
Studies examining the efficacy and safety of these 
treatments in IBD are heterogenous and controlled 
data limited[7], thus it is difficult for physicians to 
advise patients regarding these potentially deleterious 
agents. However, the ongoing consumer demand for 
alternatives to conventional therapy means that IBD 
physicians need to be alert to CAM use, its associated 
behaviours and underlying health beliefs that may 
influence conventional IBD care. 
Approximately three quarters of CAM taking IBD 
patients do not discuss its use with their IBD physician[3,8], 
thus there is a need to identify surrogate markers or 
predictors of use that may prompt discussion about CAM 
during routine consultation.
Predictors previously established fall into demo-
graphic, clinical and attitudinal categories. Independent 
demographic predictors of CAM use include younger 
age[1,5,9], female gender[1,5,9], higher educational level[5,9], 
income and employment[5,8], and middle social class at 
birth[5]. Clinical predictors are more controversial[10,11] 
but have included Crohn’s disease[9], longer disease 
duration[12], medication type[1,13], active disease[14], 
the experience of adverse effects of conventional 
medication[2,14,15], and a concurrent diagnosis of irritable 
bowel syndrome (IBS)[16].
Some studies however, have suggested that health 
attitudes and behaviours are more important than 
demographics in influencing CAM use[15,17], and there 
has been recent enthusiasm to identify attitudinal 
and behavioural predictors as these factors are 
potentially modifiable. Data regarding such predictors 
are more limited and heterogenous but suggest 
that a need for control over disease[17], desire for a 
holistic approach[17], lack of confidence in the IBD 
physician[17], poorer therapeutic relationships[18], and 
vegetarianism[5] are associated with CAM use. CAM use 
has also been suggested as a marker of psychological 
or social distress[16].
Disparity in findings between different studies may 
relate in part to cultural differences in IBD populations, 
as suggested by an Italian study which demonstrated 
regional variations in CAM type chosen, despite similar 
rates of use across the cohorts[14]. An Australian 
diabetes study suggested an effect of health care 
setting on CAM use frequency, reporting private health 
insurance as an independent predictor of CAM use[19]. 
In IBD patients in Australia, whilst overall frequency 
and potential ethnically based differences in CAM use 
have been previously examined[4], attitudinal and 
psychological predictors of its use are unexplored, as is 
the effect of the health care setting on CAM uptake. 
MATERIALS AND METHODS
Subject selection and recruitment
IBD patients from three different care settings in 
two distinct geographical locations in Australia were 
invited to participate. This method has been reported 
previously[20].
The first cohort came from a metropolitan public 
teaching hospital based specialist IBD Service 
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at Flinders Medical Centre (FMC). This is a large, 
government funded hospital, offering secondary/tertiary 
care for a local regional population of 341000 with a 
Gastroenterology inpatient and outpatient service, and 
IBD nurses available to patients within working hours. 
The second cohort consisted of IBD patients in an 
overlapping area, receiving their care via a metropolitan 
Private Practice setting. These patients were under the 
care of one of four male general Gastroenterologists 
with extensive experience in managing IBD, without 
attachment to a specialist IBD unit, or access to IBD 
specialist nurse support.  
The third cohort consisted of IBD patients cared 
for via Royal Darwin Hospital (RDH), a public hospital 
in a very remote location in Northern Australia. When 
this study was conducted, IBD care in Darwin was 
undertaken predominantly by general practitioners 
(GPs) and general surgeons, with no specialist gastro-
enterologist residing in Darwin, and no IBD nurse. The 
nearest tertiary hospital is in Adelaide, SA, more than 
3000 kilometres away. 
Potential subjects were identified from IBD data-
bases/hospital records in each location and mailed 
a questionnaire. Reminder letters were sent to non-
responders after one and three months. 
Questionnaire content 
The opening section of the questionnaire sought demo-
graphic details including age, gender, disease type, 
indigenous, relationship and employment status as well 
as current or previous history of smoking.
In the following sections, A-D, participants answered 
questions assessing: (1) views regarding conventional 
IBD medications; (2) views regarding CAM; (3) quality 
of Life; and (4) psychological and personality traits. 
Where possible, validated instruments were used as 
described below.
IBD-specific CAM use was assessed by asking 
subjects to rate the frequency with which they use 
complementary or alternative medicine to treat IBD 
on an ordinal Likert scale. A dichotomous variable was 
then generated whereby “yes” responses encompassed 
those describing their use as “often” or “very often”, 
and “no” included responses “sometimes”, “rarely” and 
“never”.
Medication Adherence was assessed using the 
Morisky 4 item Self Report Measure of Medication 
Taking Behaviour[21,22], examining predominantly 
dose omission, and covert dose reduction (CDR), 
the tendency to take less than prescribed of IBD 
medication without prescriber awareness was assessed 
as a dichotomous variable (yes/no) based on answer 
to the question “I take less than prescribed of my IBD 
medication without telling my doctor”. This has been 
previously reported[20].
Free text responses regarding attitudes towards IBD 
medication and dose modification were encouraged.
Other non-standardised attitudinal statements 
were put to subjects, seeking their views regarding 
IBD treatment beliefs and attitudes. Some Likert 
data were collapsed into categories “yes” and “no” 
for data presentation, but analysed as ordinal data 
or continuous data using factor scores for regression 
analysis.
Anxiety and Depression were measured using the 
Hospital Anxiety and Depression Scale[23], higher scores 
indicating higher levels of anxiety or depression. Quality 
of Life was measured using the reliable and valid Short 
Inflammatory Bowel Disease Questionnaire[24]. 
The Spielberger State-Trait Personality Inventory[25-27] 
was used to assess and compare depressive symptoms, 
anxiety, anger and curiosity between cohorts in both the 
immediate (state) and long term (trait or personality 
characteristic).
Statistical analysis
Comparisons between cohort means and medians 
were performed using the Kriskal Wallis test for non-
normally distributed values, and two tailed t test or 
ANOVA for normally distributed values. Pearson’s χ 2 
or Fisher’s exact test were applied as appropriate for 
categorical data. 
Significant or trend associations at univariate level 
(P < 0.10) determined which variables were inclu-
ded in regression analyses, along with demographic 
factors.
Additional continuous variables summarising themes 
across the questionnaire were generated using principal 
component analysis for ordinal data using M Plus 
software (V5.2), for the purpose of data reduction. 
An oblique (oblimin) rotation was used of 37 of the 
55 Likert scale items assessing all aspects of IBD 
treatment. An examination of the Kaiser-Meyer Olkin 
measure of sampling adequacy suggested the sample 
was favourable (KMO = 0.618). When loadings less 
than 0.4 were excluded, the analysis yielded an 8 
factor solution. Scores for each of these 8 factors were 
normally distributed. 
Binary logistic regression was used to assess 
predictors of CAM use as a dichotomous dependent 
variable, adjusting for age, gender, employment and 
relationship status. 
A P value of < 0.05 was considered statistically 
significant. Apart from factor analysis, statistical 
calculations were performed using IBM SPSS Statistics 
for Windows, version 22, 2013 (IBM Corp). The 
statistical methods for this study were reviewed by Dr 
Reme Mountifield of Flinders Medical Centre, South 
Australia.
RESULTS
Demographic data
Response rates to the survey differed between 
cohorts, with 337/612 (55.1%) of FMC and 91/180 
(50.5%) of SA private invitees participating, compared 
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= 0.805), or vegetarianism (P = 0.256) on univariate 
analysis.
Attitudes towards CAM 
Of the 206 subjects who reported regular CAM use, 
52.5% felt that it was effective (worked “well” or 
“very well”), and 20.7% had obtained the therapy at 
consultation with an alternative practitioner rather than 
independently. The vast majority (83.3%) continued to 
use conventional IBD medications concurrently. Only 
half (54.1%) discussed their CAM treatment with their 
doctor, despite 87.6% of subjects reporting feeling 
comfortable doing so.
In contrast, of those reporting previous consultation 
with an alternative practitioner only 62.2% felt 
comfortable discussing conventional therapy with 
their alternative practitioner (P < 0.001), and 16.6% 
reported the CAM practitioner discouraged their use 
of conventional IBD medication. With regard to the 
consultation experience, 10.5% felt less intimidated 
by alternative practitioners than doctors, and 16.9% 
felt more informed about IBD by the alternative 
practitioner.
Reasons for CAM use by free text response
Of the 194/206 (94.2%) subjects who offered reasons 
for their CAM use, 33.0% reported safety concerns 
regarding conventional medications. Subjects who 
elaborated further expressed the belief that “natural” 
CAM would enable them to reduce reliance on 
“chemical” conventional therapy and dose reduce or 
cease these medications. Seeking a holistic approach 
to health in some way was cited by 32.0%, and 20.6% 
report advice from family, friends, colleagues, religious 
advisors, or the internet as their main reason for use. 
A smaller proportion (14.4%) cited lack of efficacy of 
conventional medications in treating IBD. No significant 
cohort based differences were observed. 
CAM use and treatment attitude associations-univariate 
analysis
Attitudinal and behavioural associations of CAM use on 
univariate analysis are presented in Table 3. 
with 35/100 (35%) in Darwin (P < 0.0001). Non 
respondents did not differ from respondents by 
gender (P = 0.2), but there was a trend toward non 
respondents being younger than respondents (mean 
age 43.7 vs 50.3 years, P = 0.065) Darwin subjects 
were more likely be current or previous smokers, and 
to receive a disability support pension. This population 
has been previously reported[20]. Demographic data 
are summarised in Table 1. 
Frequency, demographic and clinical associations of 
regular CAM use
Many subjects (45.4% overall) reported regular 
use of CAM, with no significant difference in usage 
frequency between cohorts (P = 0.594) (Figure 1). 
Distribution of CAM type used is presented in Table 2, 
and was not significantly different between cohorts (P 
= 0.626). The regular use of more than one CAM type 
(i.e., physical as well as homeopathic methods) was 
reported by 64.5% of subjects.
Rates of CAM use were higher amongst younger 
(46.69 vs 53.41 years, P < 0.001), female (52.0% vs 
35.5%, P < 0.001), and permanently employed (51.1% 
vs 37.4%, P = 0.004) subjects. However, CAM usage 
did not differ by disease type (P = 0.394), conventional 
medication pill burden (P = 0.784), smoking status (P 
Table 1  Demographics in contrasting inflammatory bowel 
disease cohorts
FMC 
(n  = 337)
Private 
(n  = 91)
Darwin 
(n  = 35)
P  value
Mean age respondents (yr) 50.3 52.2 48.4 0.35
Mean age non respondents 
(yr)
43.0 48.1 39.9 0.20
Female respondents 60.2% 60.4%    60% 0.99
Female non respondents 55.7% 52.4% 40.7% 0.07
Crohn’s disease 55.2% 57.1% 48.6% 0.70
Indigenous subjects   0.9%   1.1%   2.9% 0.37
Current smokers 11.1% 13.6% 17.1% 0.09
Previous smokers 25.8% 25.0% 42.9% 0.09
Receiving disability support 
pension
  1.8%   1.1%   5.7%   0.006
Employed 58.7% 56.7% 62.9% 0.19
Currently partnered 92.2 95.3 93.3 0.61
Table 2  Distribution of complementary and alternative therapy 
types reported by inflammatory bowel disease subjects 
Primary (first mentioned) CAM type Percentage of total CAM 
reported overall
Herbal products (e.g., slippery elm, 
aloe vera juice, olive oil extract, green 
lipped mussel oil, other herbs)
30.50%
Probiotics 22.60%
Fish oil 12.10%
Chinese medicine 10.50%
Acupuncture, massage, magnetism 10.50%
Other (prayer, meditation, exercise, 
dietary supplements, hypnotherapy)
13.70%
CAM: Complementary and alternative therapy.
47%
46%
45%
44%
43%
42%
41%
39%
38%
37%
36%
FMC              Private             Darwin
P  = 0.626
Figure 1  Proportion of subjects in each cohort reporting regular com­
plementary medicine use.
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Of all subjects including CAM users and non-users, 
57.3% reported family or friends using CAM for any 
health purpose. Those with CAM-using contacts was 
more likely to use it themselves for IBD (59.9% vs 
40.1%, P = 0.004), free text responses suggesting 
that type of CAM chosen was influenced by social 
contacts.
The 54.9% of subjects reporting adverse effects 
of conventional medications were more likely to 
use CAM (P = 0.025), as were the 26.9% reporting 
regular self-initiated dose reduction of medication (P < 
0.001). Lack of doctor communication satisfaction was 
reported by only a small proportion of patients (2.4%) 
but was associated with CAM use, as was seeking of 
psychological or psychiatric treatment (P < 0.001) 
when analysed as individual items.
Analysis of HADS, QOL and Spielberger mean 
scores suggested that increased anxiety, higher quality 
of life and lower depression scores were associated 
with increased CAM use, whilst personality type did not 
influence rate of use (Table 4). 
Independent predictors of regular CAM use 
After adjustment for age, gender, disease type and 
employment level, attitudinal and psychological 
predictors of regular CAM use using binary logistic 
regression analysis are shown in Table 5. This model 
explained a significant proportion of variance in low 
adherence rates (adjusted pseudo R squared 0.217, 
goodness of fit Hosmer Lemeshow P = 0.161).
After adjustment for demographics a trend was 
observed toward higher CAM usage amongst non-
smokers (OR = 1.299, 95%CI: 0.993-1.698, P = 
0.056).
Covert dose reduction, lower depression scores 
and subjects’ propensity to seek psychological help 
predicted CAM use, the latter factor analysis generated 
variable encompassing use of antidepressants, and 
consultations with counsellors, psychologists or 
psychiatrists (Table 5). Similarly, the factor analysis 
generated variable assessing dissatisfaction with 
doctor communication was an independent predictor 
of CAM use, and included satisfaction level with 
doctor relationship, doctor communication style, 
level of comfort in asking questions of doctor, and 
comprehension of information provided during 
consultation.
DISCUSSION
This study demonstrates the high frequency of CAM 
use amongst IBD patients in Australia, and suggests 
that such use occurs independently of health care 
setting and geography. Newly identified attitudinal 
and psychological risk factors include dissatisfaction 
with patient-doctor communication, CAM use by social 
contacts and lower depression scores. We confirm both 
the known demographic risk factors for CAM use and 
known behavioural associations such as covert dose 
reduction, psychotherapeutic support seeking, and 
adverse effects of conventional medications. 
The frequency of regular CAM use was slightly 
Table 3  Attitudinal and behavioural associations of regular 
complementary and alternative therapy use - univariate 
analysis  n  (%)
Regular CAM use P  value
No Yes
Deliberate dose reduction No 197 (61.4) 124 (38.6) < 0.001
Yes   46 (38.7)   73 (61.3)
Family or friends use 
alternative treatments
No   88 (55.0)   72 (45.0)    0.004
Yes   85 (40.1) 127 (59.9)
Experienced adverse effects 
conventional IBD meds
No   89 (59.7)   60 (40.3)    0.025
Yes 129 (48.3) 138 (51.7)
Satisfied with 
communication with IBD 
doctor
No   1 (9.1)   10 (90.9)    0.002
Yes 246 (55.7) 196 (44.3)
Previous psychological 
counselling
No 197 (61.6) 123 (38.4) < 0.001
Yes   49 (38.0)   80 (62.0)
CAM: Complementary and alternative therapy; IBD: Inflammatory bowel 
disease.
Table 4  Anxiety, depression, quality of life and personality 
traits in users vs non users of cam in inflammatory bowel 
disease - univariate analysis
Regular 
CAM use
Mean SD SE 2 tailed 
P  value
Anxiety (HADS) No 8.3312 3.50750 0.09032    0.017
Yes 8.6365 3.18002 0.08969
Depression 
(HADS)
No 6.8774 2.85105 0.07354    0.002
Yes 6.5556 2.67318 0.07540
SIBDQ No 56.0152 9.71282 0.25137 < 0.001
Yes 58.1210 9.57504 0.27126
Trait anxiety No 21.0042 2.53088 0.06539    0.341
Yes 21.0957 2.48538 0.07019
Trait curiosity No 25.831 6.13307 0.15836    0.916
Yes 25.8549 5.71720 0.16158
Trait anger No 11.3837 3.93971 0.10169    0.385
Yes 11.5097 3.60996 0.10202
Trait depression No 18.9960 3.59568 0.09293    0.744
Yes 19.0385 3.12376 0.08818
Table 5  Independent attitudinal predictors of regular 
complementary and alternative therapy use in inflammatory 
bowel disease - logistic regression analysis 
Odds ratio 95%CI P  value
Covert dose reduction 2.588 2.135-3.138 < 0.001
Seeking psychological treatment 1.888 1.563-2.280 < 0.001
Family and friends are regular 
CAM users
1.710 1.434-2.044 < 0.001
Dissatisfied with doctor 
communication
1.561 1.304-1.869 < 0.001
Adverse effects conventional 
medications
1.208 1.006-1.467    0.043
Depression (HADS) 0.910 0.878-0.943 < 0.001
Quality of life (SIBDQ) 1.022 1.011-1.032 < 0.001
CAM: Complementary and alternative therapy.
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higher in our study population (45.4%) than reported 
previously in Australia[4], but within the range reported 
internationally[1,4,28]. Similarly to the Italian study 
assessing regional variation in CAM use[14], we found 
no difference in overall rates of CAM use between 
cohorts, but in contrast did not find regional variation 
in the type of CAM chosen either. Some variation 
in choice of CAM type is seen between populations 
globally, our predominantly Caucasian cohorts being 
comparable with New Zealand IBD subjects amongst 
whom herbs and vitamins were most commonly 
used[5]. Interestingly nearly two thirds of subjects used 
more than one type of CAM, however, overlapping 
physical and homeopathic methods and rendering 
further analysis by individual CAM type difficult. 
Although the patient doctor relationship is known to 
affect CAM use[29], the more specific aspect of doctor 
communication quality as a predictor has not been 
previously reported. Subjects who were dissatisfied 
with the style of communication from their doctor, did 
not feel information was presented in a comprehensible 
way, or felt that the consultation environment did not 
encourage patient questions, were significantly more 
likely to use CAM after adjustment for other factors. 
A Canadian study found that the wish for a more 
active role in treatment decisions was associated with 
CAM use[17], and the desire for more information from 
doctors was predictive of use in an Italian cohort[30]. 
The significant influence of CAM use behaviours 
amongst social contacts on CAM uptake decisions in 
IBD individuals has also not been previously reported. 
In our study this was adjusted for age, gender, and 
employment level but not for other demographics 
which may be common across family members and 
confound the association. Such influence would not be 
surprising, however, given the effect of marital status, 
for example, on other medication taking behaviours 
such as adherence to conventional therapy in IBD[31]. 
A study of healthy adolescents found that social 
contacts exert significant influence over the decision 
to use CAM[32], and further work to investigate this 
in IBD populations is warranted, especially given 
the escalating influence of social media on everyday 
decision making. 
Previously reported predictors including CDR 
of conventional medications, adverse effects of 
medications and increased QOL were confirmed in this 
study. Free text responses strongly suggested that 
IBD CAM users tend to reduce rather than omit doses 
of conventional medications on the assumption that 
CAM use will provide a “medication sparing” effect, the 
aim being to minimise adverse effects of conventional 
medications. This newly described phenomenon is the 
subject of a separate publication[20], which suggests 
that similar underlying health beliefs and desires 
drive both CAM uptake and CDR behaviour. Although 
abundant free text data from this study support 
this hypothesis, formal path analysis has yet to be 
undertaken to confirm the direction of causality in the 
association between CAM use and CDR.
Those subjects seeking psychological input such 
as counselling, psychologist or psychiatrist review, or 
antidepressant medication were significantly more 
likely to use CAM in this study, and this has been 
previously demonstrated in two European studies[1,13]. 
Free text responses suggested that CAM was not 
being prescribed by the psychological care provider, 
but rather both behaviours were the result of a desire 
for a holistic health approach with active ways of 
coping, and this has been previously reported[13]. 
This may be supported by our new finding that lower 
depression scores were associated with CAM use, 
perhaps indicating the presence of successfully treated 
depression in this population who may be more 
receptive to psychology.
Gastroenterologist awareness of CAM use was 
similar in our study to the 46% seen in a French web 
based study of IBD patients[10], but greater than that 
found elsewhere[3,8,33]. This communication gap may 
be contributed to by both consultation participants, 
a study examining CAM use in IBD patients from 
the physician perspective finding that only 8% of 
IBD physicians had initiated CAM conversations 
themselves, and only around 50% were comfortable 
discussing CAM with their patients[33]. 
The confirmation of previously reported demographic 
and attitudinal CAM predictors suggests that our study 
population is similar to others, and thus the results 
generalizable to some extent. The limitations of this 
study include the small amount of clinical information 
obtainable from subjects by self-report, including 
disease activity and response to conventional therapy. 
Additionally, comparisons between cohorts were 
hampered by the uneven group sizes and response 
rates across different treatment settings. Statistical 
analysis differentiating by CAM type is likely to be 
important but was not feasible in this study as most 
subjects (64.5%) reported using more than one 
therapy type. Also, the definition of CAM is not uniform 
across studies and in this case was defined as what 
subjects felt was outside of “conventional” therapy.
CAM use is highly prevalent and appears inde-
pendent of care setting and geography in IBD, and its 
importance to patients is often under-recognised by 
physicians. The quality of patient doctor communication 
is a key determinant, and failure to actively address 
CAM use in consultation may promote patient “default” 
to other advice sources such as family, friends and 
other social contacts, which ultimately undermines the 
patient doctor relationship.
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Background 
Complementary and alternative medicine (CAM) use is common in inflammatory 
bowel disease (IBD), and some demographic and clinical predictors have been 
established. This article reports a cross sectional survey of Australian subjects 
from contrasting care settings with IBD, focussing on the frequency and type of 
CAM use, and its behavioural and attitudinal predictors.
Research frontiers 
In the world of ever increasing influence on everyday health decisions from 
social contacts via social media and the internet, physician understanding of 
patient context needs to evolve to promote strong and open partnerships with 
patients in making treatment decisions. 
Innovations and breakthroughs
This study demonstrates that patients with IBD make decisions regarding 
CAM use that are subject to multiple inputs, only one of those inputs being 
the treating physician. The importance of unqualified health advice from 
social contacts needs to be acknowledged and addressed in order to optimise 
adherence to conventional therapy. 
Applications 
IBD physicians need to attend more closely than ever to clear communication 
with patients regarding the risks and benefits of conventional therapy, and 
enquire about CAM use to better understand the patient’s context. Patient 
understanding of disease and therapy should be routinely assessed by 
physicians in order to correct misperceptions introduced by social contacts, 
alternative practitioners and the internet that may undermine successful IBD 
treatment.
Peer-review
This well presented study makes an important contribution to the literature as it 
highlights the broader context of individuals with IBD, reporting new behavioural 
predictors of complementary medicine uptake in this population which warrant 
attention during consultation.
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